CARA THERAPEUTICS INC

Cara Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

05 4 2022 07:00:01 提供 Nasdaq GlobeNewswire

Cara Therapeutics Announces Biomarker Data from KALM-1 and KALM-2 Trials of KORSUVA™ (difelikefalin) Injection Selected for Presentation at National Kidney Foundation Spring Clinical Meetings 2022

04 4 2022 16:01:00 提供 Nasdaq GlobeNewswire

Cara Therapeutics Announces Oral KORSUVA™ (difelikefalin) Improves Itch and Inflammatory Biomarkers in Atopic Dermatitis Patients with Moderate-To-Severe Pruritus

28 3 2022 07:00:00 提供 Nasdaq GlobeNewswire

Cara Therapeutics Announces Oral KORSUVA™ (difelikefalin) Data Selected for Late-Breaking Presentation at 2022 American Academy of Dermatology Annual Meeting

08 3 2022 16:01:00 提供 Nasdaq GlobeNewswire

Cara Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

01 3 2022 16:01:00 提供 Nasdaq GlobeNewswire

Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients

25 2 2022 07:15:00 提供 Nasdaq GlobeNewswire

Cara Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022

22 2 2022 16:01:00 提供 Nasdaq GlobeNewswire

Cara Therapeutics to Host Virtual R&D Day on March 11, 2022

18 2 2022 07:00:00 提供 Nasdaq GlobeNewswire

Cara Therapeutics Announces Difelikefalin (KORSUVA™) Injection Achieves Positive Topline Results in Phase 3 Clinical Study in Japan for the Treatment of Pruritus in Hemodialysis Patients

10 1 2022 08:00:02 提供 Nasdaq GlobeNewswire

Cara Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

03 1 2022 16:01:00 提供 Nasdaq GlobeNewswire

Cara Therapeutics Announces CMS Grants TDAPA to KORSUVA™ (difelikefalin) Injection

20 12 2021 07:00:00 提供 Nasdaq GlobeNewswire

Cara Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

18 11 2021 08:30:00 提供 Nasdaq GlobeNewswire

Cara Therapeutics to Present at Upcoming Investor Conferences

09 11 2021 16:30:00 提供 Nasdaq GlobeNewswire

Cara Therapeutics Reports Third Quarter 2021 Financial Results

08 11 2021 16:01:03 提供 Nasdaq GlobeNewswire

Cara Therapeutics Announces CEO Transition

03 11 2021 08:00:03 提供 Nasdaq GlobeNewswire

Cara Therapeutics to Announce Third Quarter 2021 Financial Results on November 8, 2021

01 11 2021 16:15:00 提供 Nasdaq GlobeNewswire

Cara Therapeutics Presents Late-Breaking Results of KARE Phase 2 Trial of Oral Difelikefalin (Oral KORSUVA™) in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus at the 2021 European Academy of Dermatology and Venereology (EADV) Virtual Congress

04 10 2021 07:00:00 提供 Nasdaq GlobeNewswire

Cara Therapeutics Announces Late-Breaking Presentation at 2021 European Academy of Dermatology and Venereology (EADV) Virtual Congress

29 9 2021 07:00:00 提供 Nasdaq GlobeNewswire

Cara Therapeutics to Present at the the 2021 Cantor Virtual Global Healthcare Conference

24 9 2021 07:00:00 提供 Nasdaq GlobeNewswire

Cara Therapeutics and Vifor Pharma announce U.S. FDA approval of KORSUVA™ (difelikefalin) injection for the treatment of moderate-to-severe pruritus in hemodialysis patients

23 8 2021 15:41:29 提供 Nasdaq GlobeNewswire